Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000899243-18-006956

Options or other derivatives

  • Chief Executive Officer acquired 136,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Kulkarni Samarth Chief Executive Officer 2018-03-07 Grant or award · Stock Option (Right to Buy) +136,000 136,000 D
Loading xslF345X03/doc4.xml…